Literature DB >> 16239358

Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir.

Chin-chung Lin1, Christine Xu, Alice Teng, Li-Tain Yeh, Janet Peterson.   

Abstract

The pharmacokinetics of pradefovir and adefovir, 9-(2-phosphonylmethoxyethyl) adenine (PMEA), was evaluated in healthy male volunteers after oral dosing of pradefovir (10, 30, or 60 mg). Pradefovir was absorbed rapidly. The maximum serum concentration, the area under the concentration-time curve between 0 and 96 hours after dosing (AUC(0-96)), and the area under the plasma concentration versus time curve from time 0 to infinity (AUC(0-infinity)) of pradefovir and PMEA increased with the dose of pradefovir. The ratio of PMEA to pradefovir for AUC(0-96) and AUC(0-infinity) ranged from 1.4 to 1.8. Renal clearance of pradefovir (18-31 L/h) increased with the dose of pradefovir and was greater than glomerular filtration. The fraction of total body clearance due to renal clearance was low (0.045 to 0.083), suggesting that metabolic clearance played a significant role in the clearance of pradefovir in man. In addition, an evaluation of the food effect was conducted at the 30-mg dose. The results indicate that food intake has no effect on the extent of exposure of pradefovir and PMEA but may decrease the rate of systemic availability of PMEA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239358     DOI: 10.1177/0091270005280644

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.

Authors:  Chin-chung Lin; Che Fang; Salete Benetton; Gui-fen Xu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Antiviral therapy and resistance with hepatitis B virus infection.

Authors:  Hans L Tillmann
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 3.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

4.  Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects.

Authors:  Yanhua Ding; Hong Zhang; Xiaojiao Li; Cuiyun Li; Guiling Chen; Hong Chen; Min Wu; Junqi Niu
Journal:  Hepatol Int       Date:  2017-05-30       Impact factor: 6.047

5.  Development and Validation of a Sensitive LC-MS-MS Method for the Determination of Adefovir in Human Serum and Urine: Application to a Clinical Pharmacokinetic Study.

Authors:  Ye Zhang; Lu Shen; Ying Zhan; Qing-Qing Xiao; Jin Yang
Journal:  J Chromatogr Sci       Date:  2015-12-10       Impact factor: 1.618

Review 6.  Novel therapies in hepatitis B and C.

Authors:  Bart Takkenberg; Joep de Bruijne; Christine Weegink; Peter Jansen; Hendrik Reesink
Journal:  Curr Gastroenterol Rep       Date:  2008-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.